Bellvitge University Hospital

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Source

• Recruiting

  Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

  2026-526026-40-00· Phase 2/3· Source

• Recruiting

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· Phase 2· Source

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Source

• Recruiting

  Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia.

  2025-524794-16-00· Phase 4· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· Source

• Not yet recruiting

  A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

  2025-525033-31-00· Phase 2· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  2025-524335-39-00· Phase 3· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

  2026-525897-20-00· Phase 1· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Source

• Recruiting

  Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

  NCT07695701· Phase 4· Source

• Not yet recruiting

  Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon

  NCT07650578· Source

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)

  2025-524040-35-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· Source

• Recruiting

  A Phase 3 Trial of K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg

  2025-523739-20-00· Phase 3· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Source

• Recruiting

  A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT07571200· Phase 1· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· Phase 3· Source

• Not yet recruiting

  REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

  NCT07611188· Source

• Not yet recruiting

  Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

  NCT07074782· Source

• Recruiting

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

  NCT07221669· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Not yet recruiting

  Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia

  NCT07555743· Phase 4· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Source

• Not yet recruiting

  Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study

  2025-524751-32-00· Phase 4· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Source

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· Source

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Source

• Not yet recruiting

  Comparison of Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)

  NCT07368218· Source

• Recruiting

  ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

  NCT07484009· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· Source

• Recruiting

  Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC

  NCT07818135· Source

• Recruiting

  Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.

  NCT07851779· Phase 4· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Source

• Recruiting

  TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT07190300· Phase 1/2· Source

• Recruiting

  Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

  NCT07190690· Source

• Recruiting

  A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  NCT07266831· Phase 2/3· Source

• Recruiting

  A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

  2024-515125-28-00· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure14 recruiting
• Coronary artery disease8 recruiting
• ALS (motor neurone disease)7 recruiting
• Amyloidosis6 recruiting
• HIV6 recruiting
• Stroke6 recruiting
• Myasthenia gravis5 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Macular degeneration4 recruiting
• Atrial fibrillation3 recruiting
• Bladder cancer3 recruiting
• Depression3 recruiting
• Multiple sclerosis3 recruiting
• Obesity3 recruiting
• Pancreatic cancer3 recruiting
• Prostate cancer3 recruiting
• Asthma2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Gastric and esophageal cancer2 recruiting
• Huntington's disease2 recruiting
• Melanoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• ANCA-associated vasculitis1 recruiting
• Bipolar disorder1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Diabetic eye disease1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glaucoma1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Ovarian cancer1 recruiting
• Spinal muscular atrophy1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

  NCT07287397· Phase 1/2· Source

• Completed

  A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis

  2024-517814-13-00· Phase 2· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Source

• Completed

  Sapphire 3 CTO Study

  NCT06358508· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Source

• Completed

  Validation of a Score for Supplementation Needs of Vitamins, Micronutrients and Proteins After Bariatric Surgery

  NCT07268209· Source

• Completed

  Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switch)

  2023-504192-25-00· Phase 4· Source

• Completed

  A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

  NCT06195930· Phase 2· Source

• Completed

  Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease.

  2023-506432-32-00· Phase 4· Source

• Completed

  A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

  NCT06131372· Phase 2· Source

• Completed

  A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment

  2023-506509-21-00· Phase 1· Source

• Active, not recruiting

  A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

  NCT06282159· Phase 2· Source

• Completed

  THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)

  2023-507304-32-00· Phase 4· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Source

• Completed

  Impact of the Implementation of a Telemedicine Program on Patients Diagnosed With Asthma

  NCT06116292· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Active, not recruiting

  Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT06122779· Phase 2· Source

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Source

• Completed

  Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

  2024-512646-42-00· Phase 2· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· Source

• Completed

  A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74)

  NCT05492500· Phase 2· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Source

• Terminated

  Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

  NCT05866926· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· Source

• Completed

  Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

  NCT05184088· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

  NCT04020055· Phase 3· Source

• Completed

  Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities

  NCT05549180· Phase 4· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

  NCT05032066· Phase 2· Source

• Completed

  Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  NCT05097989· Phase 2· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Source

• Completed

  SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

  NCT04889183· Phase 3· Source

• Completed

  A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

  NCT05318976· Phase 2· Source

• Completed

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· Phase 3· Source

Trial sites

• Hospital Universitari de Bellvitge0 trials
• Bellvitge University Hospital9 trials
• Hospital Universitari Bellvitge2 trials
• Hospital Universitari de Bellvitge24 trials
• Hospital Universitari de Bellvitge (HUB)1 trial
• Hospital Universitari de Bellvitge / Nephrology Dpt0 trials
• Hospital Universitari de Bellvitge - Site #5630 trials
• Hospital University Bellvitge0 trials
• Hosp. Univ. de Bellvitge0 trials
• Hosp. Univ. de Bellvitge - Ico Hospitalet - Duran I Reynals1 trial
• IDIBELL, Hospital Universitari de Bellvitge.1 trial
• ResoFus Alomar (Hospital Universitari De Bellvitge)1 trial
• Retina Unit, Department of Ophthalmology, Bellvitge University Hospital1 trial
• University Hospital of Bellvitge2 trials
• Hospital Universitari de Bellvitge1 trial
• Hospital Universitari de Bellvitge1 trial
• Bellvitge University Hospital187 trials
• 7240053 - Hospital Universitari de Bellvitge (IDIBELL)1 trial
• Hopital Universitari de Bellvitge1 trial
• Hospital Universitari de Bellvitge34 trials
• Hospital Universitari de Bellvitge /ID# 2082070 trials
• Hospital Universitari de Bellvitge /ID# 2154271 trial
• Hospital Universitari de Bellvitge /ID# 2463260 trials
• Hospital Universitari de Bellvitge /ID# 2485131 trial
• Hospital Universitari de Bellvitge /ID# 2611981 trial
• Hospital Universitari de Bellvitge /ID# 2626410 trials
• Hospital Universitari de Bellvitge /ID# 2639321 trial
• Hospital Universitari de Bellvitge /ID# 2682241 trial
• Hospital Universitari de Bellvitge /ID# 985841 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Lupus (SLE)18 works · 2 trials
• ALS (motor neurone disease)16 works · 15 trials
• Amyloidosis15 works · 11 trials
• Idiopathic pulmonary fibrosis13 works · 20 trials
• Myasthenia gravis7 works · 10 trials
• ANCA-associated vasculitis5 works · 1 trials